Evidence map›Paper›PMID 37364599›Full record

ArticleCancer science2023

Clinical and prognostic features of Langerhans cell histiocytosis in adults.

Aki Sato, Masayuki Kobayashi, Nozomi Yusa, Miho Ogawa, Eigo Shimizu, Toyotaka Kawamata, Kazuaki Yokoyama, Yasunori Ota, Tatsuo Ichinohe, Hitoshi Ohno and 7 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer science, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
3.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 12 institutions in 1 country.

Aki SatoDepartment of Hematology and Oncology, Institute of Medical Science Research Hospital, University of Tokyo, Tokyo, Japan.ORCID https://orcid.org/0000-0003-1714-1347
Masayuki KobayashiDepartment of Hematology, Tokyo Metropolitan Bokutoh Hospital, Tokyo, Japan.ORCID https://orcid.org/0000-0002-9194-9320
Nozomi YusaDepartment of Applied Genomics, Institute of Medical Science Research Hospital, University of Tokyo, Tokyo, Japan.
Miho OgawaDivision of Hematopoietic Disease Control, Institute of Medical Science, University of Tokyo, Tokyo, Japan.
Eigo ShimizuDivision of Health Medical Intelligence, Human Genome Center, Institute of Medical Science, University of Tokyo, Tokyo, Japan.
Toyotaka KawamataDepartment of Hematology and Oncology, Institute of Medical Science Research Hospital, University of Tokyo, Tokyo, Japan.ORCID https://orcid.org/0000-0003-1311-8756
Kazuaki YokoyamaDepartment of Hematology and Oncology, Institute of Medical Science Research Hospital, University of Tokyo, Tokyo, Japan.
Yasunori OtaDepartment of Diagnostic Pathology, Institute of Medical Science Research Hospital, University of Tokyo, Tokyo, Japan.
Tatsuo IchinoheDepartment of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.
Hitoshi OhnoDepartment of Hematology, Tenri Hospital, Nara, Japan.ORCID https://orcid.org/0000-0002-4348-4450
Yasuo MoriDepartment of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan.
Emiko SakaidaDepartment of Hematology, Chiba University Hospital, Chiba, Japan.
Tadakazu KondoDepartment of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.ORCID https://orcid.org/0000-0002-8959-6271
Seiya ImotoDivision of Health Medical Intelligence, Human Genome Center, Institute of Medical Science, University of Tokyo, Tokyo, Japan.
Yasuhito NannyaDepartment of Hematology and Oncology, Institute of Medical Science Research Hospital, University of Tokyo, Tokyo, Japan.
Kinuko MitaniDepartment of Hematology and Oncology, Dokkyo Medical University, Tochigi, Japan.
Arinobu TojoInstitute of Innovation Advancement, Tokyo Medical and Dental University, Tokyo, Japan.
Shiga University of Medical Science Hospital · JPTokyo Medical University · JPTokyo University of Science · JPChiba University Hospital · JPDokkyo Medical University · JPHiroshima University · JPKyoto University · JPKyushu University · JPTenri Hospital · JPTokyo Medical and Dental University · JPTokyo Medical University Hospital · JPTokyo Metropolitan Bokutoh Hospital · JP

Funding

the Japanese National Research Group on Idiopathic Bone Marrow Failure Syndromes 20FC1018
6 · The paper itself

Abstract

Langerhans cell histiocytosis (LCH) is a rare disease characterized by clonal expansion of CD1a

Indexed as

Histiocytosis, Langerhans-CellNeoplasmsAdultAgedAged, 80 and overChildFemaleHumansMaleMiddle AgedMutationPrognosisProgression-Free SurvivalProto-Oncogene Proteins B-rafYoung AdultProto-Oncogene Proteins B-rafadultBRAF mutationLangerhans cell histiocytosisnationwide surveyprognosis

Identifiers

PMID37364599
PMCPMC10475785
OpenAlexW4382045886

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.